The potential of a Chikungunya vaccine - unpredictably attractive


19-06-2018

This month VacZine Analytics releases MarketVIEW: Chikungunya vaccines. As more countries report local or autochthonous transmission of this problematic virus, and two vaccines receive priority designation, VacZine Analytics investigates commercial potential.

Chikungunya virus (CHIK) is an arthropod-borne RNA virus (arbovirus) which causes an acute illness including fever, skin rash and incapacitating arthralgia. In some cases, the virus can cause recurrent disease (post-CHIK rheumatic disorder), neurological complications and severe neonatal disease (encephalopathy). CHIK is not generally considered a life-threatening disease, with an estimated case-fatality rate of 0.1%. However, concerns are increasing. In 2016, the Brazilian Ministry of Health recognised more than 200 deaths related to CHIK infection. Moreover, the geographical range of Chikungunya is increasing. The number of countries reporting local or autochthonous transmission has approximately doubled since 2014 (US CDC figures). One main concern is that any country that has establishment of the mosquito vector Aedes Albopictus could experience a significant outbreak, including a large part of the United States and Mediterranean countries.

A number of potential CHIK vaccine candidates (based on various approaches) are now in the clinical stages of development including those from PaxVax, Inc, Themis Bio GmbH, Valneva Austria GmbH. The PaxVax, Inc and Themis Bio vaccine candidates received fast-track designation by the FDA and EU in May/June 2018 respectively. A CHIK vaccine could be used in vulnerable populations in both endemic public/private markets and possibly in Western travelers (profile dependent). 

This MarketVIEW product is a comprehensive commercial evaluation containing an Executive Presentation (~110 slides) and MS Excel Workbook (.xls) examining the potential (value/volume) of a prophylatic Chikungunya vaccine to 2035. The prospects of the vaccine in “First time” and “Repeat” Western travelers (Visiting Friends/Family and Business + Other), endemic markets (public + private) and for military/domestic stockpile use are discussed with assumptions clearly outlined. A full review of disease background, latest epidemiology/outbreaks and competitor/R&D activity are also provided. 

For more information please contact info@vaczine-analytics.com or www.vaczine-analytics.com

VacZine Analytics, world-leading supplier of vaccine-related commercial analyses is a trading division of Assay Advantage Ltd (UK Company No: 5807728, UK VAT: 883584084)

 

VacZine Analytics is an established strategic research publisher based in the United Kingdom.

VacZine Analytics Ltd (Assay Advantage)